What is GE HealthCare Technologies Inc. (GEHC) DCF Fair Value and Intrinsic Value in 2026?

GE HealthCare Technologies Inc. (GEHC) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is GE HealthCare Technologies Inc.'s historical Return on Invested Capital (ROIC) and Moat Rating?

GE HealthCare Technologies Inc. operates in the Healthcare sector (Medical Devices) with an economic moat rating of NARROW. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is GE HealthCare Technologies Inc.'s financial health rating and Piotroski F-Score?

GE HealthCare Technologies Inc.'s balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor GE HealthCare Technologies Inc. (GEHC) for quarterly SEC filing thesis breaks?

LocalAlpha audits GE HealthCare Technologies Inc.'s 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksGEHC

GEHC

GE HealthCare Technologies Inc.Healthcare / Medical DevicesINTACT

GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.

Share Price

$63.43

52W: $58.75 - $89.77

DCF Fair Value

$53.54

-18.5% Premium

Thesis Hub

P/E (TTM)

14.6x

ROIC

11.3%

Operating Margin

15%

FCF Yield

5.5%

Debt / Equity

0.94x

Piotroski Score

8/9

Altman Z-Score

3.81

Market Cap

$28.9B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($53.54)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$53.54

MOS Buy Target (-25%)

$40.16

Valuation Overlays: DCF Fair Value ($53.54) 25% MOS Buy Target ($40.16) Revised Graham ($78.77) Graham Number ($48.71)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$63.43

DCF Fair Value

$53.56

-18.4% Premium

Starting Free Cash Flow ($M)$1,573M

$100M$1,573M (Reported)$50,000M

Stage 1 Growth (Years 1-5)7.5%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$8,400M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$14.0B

PV of Terminal Value

$18.7B

Implied Enterprise Value

$32.8B

Implied Equity Value

$24.4B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$1,691	$1,818	$1,954	$2,101	$2,258	$2,360	$2,466	$2,577	$2,693	$2,814
Present Value (PV)	$1,551	$1,530	$1,509	$1,488	$1,468	$1,407	$1,349	$1,293	$1,240	$1,189

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-30.2% Premium

$48.71

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $4.34BVPS: $24.30

Revised Graham Formula+19.5%

$78.77

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings5.2% Yield

$3.28 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $1.5BYield: 5.2%

Reverse DCF: Market Growth Expectation

MODEST BARRIER

4.5% CAGR (Next 10 Yrs)

At the current price of $63.43, the market is assuming the business will compound Free Cash Flow at 4.5% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

✓ Low market hurdle: Easy for a wide-moat compounder to beat.

Autonomous Thesis Underwriting

Surveil GEHC with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for GE HealthCare Technologies Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 15% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track GEHC & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: GE HealthCare Technologies Inc. (GEHC) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for GE HealthCare Technologies Inc..

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, GE HealthCare Technologies Inc. has an estimated DCF intrinsic fair value of $53.54 per share compared to its current market price of $63.43. This represents an estimated 18.5% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $48.71.